Treatment of renal fibrosis by rebalancing TGF-β/Smad signaling with the combination of asiatic acid and naringenin.

PubWeight™: 0.84‹?›

🔗 View Article (PMID 26474462)

Published in Oncotarget on November 10, 2015

Authors

Xiao-ming Meng1,2, Yun Zhang1,3, Xiao-Ru Huang1, Gui-ling Ren2, Jun Li2, Hui Yao Lan1

Author Affiliations

1: Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR.
2: School of Pharmacy, Anhui Medical University, An Hui, China.
3: Department of Dermatology, Foshan Hospital of TCM, Foshan, China.

Articles cited by this

Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest (2003) 4.58

TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol (2011) 2.78

Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol (2011) 2.71

A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem (1995) 2.71

TGF-beta in renal injury and disease. Semin Nephrol (2007) 2.65

Smad3 mediates cardiac inflammation and fibrosis in angiotensin II-induced hypertensive cardiac remodeling. Hypertension (2010) 2.39

Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol (2003) 2.24

Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J Am Soc Nephrol (2010) 1.89

IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int (2006) 1.80

Smad3 deficiency attenuates renal fibrosis, inflammation,and apoptosis after unilateral ureteral obstruction. Kidney Int (2004) 1.69

The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes (2010) 1.68

Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant (2008) 1.56

Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res (2011) 1.49

Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes (2010) 1.48

Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci U S A (2004) 1.41

Role of the TGF-β/BMP-7/Smad pathways in renal diseases. Clin Sci (Lond) (2013) 1.40

miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia (2013) 1.39

TGF-β/Smad signaling in renal fibrosis. Front Physiol (2015) 1.36

Smad7 as a therapeutic agent for chronic kidney diseases. Front Biosci (2008) 1.22

Disruption of Smad4 impairs TGF-β/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney Int (2011) 1.20

Inhibition of LPS-induced NO and PGE2 production by asiatic acid via NF-kappa B inactivation in RAW 264.7 macrophages: possible involvement of the IKK and MAPK pathways. Int Immunopharmacol (2007) 1.20

Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int (2007) 1.18

How does TGF-β mediate tubulointerstitial fibrosis? Semin Nephrol (2012) 1.14

Asiatic acid inhibits liver fibrosis by blocking TGF-beta/Smad signaling in vivo and in vitro. PLoS One (2012) 1.14

Smad3 mediates ANG II-induced hypertensive kidney disease in mice. Am J Physiol Renal Physiol (2012) 1.09

Kidney-targeting Smad7 gene transfer inhibits renal TGF-β/MAD homologue (SMAD) and nuclear factor κB (NF-κB) signalling pathways, and improves diabetic nephropathy in mice. Diabetologia (2011) 1.06

Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int (2004) 1.06

Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int (1998) 1.06

Smad ubiquitination regulatory factor-2 in the fibrotic kidney: regulation, target specificity, and functional implication. Am J Physiol Renal Physiol (2008) 1.04

Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells. Pharm Res (2006) 1.03

Diverse roles of TGF-β receptor II in renal fibrosis and inflammation in vivo and in vitro. J Pathol (2012) 1.01

Disruption of Smad7 promotes ANG II-mediated renal inflammation and fibrosis via Sp1-TGF-β/Smad3-NF.κB-dependent mechanisms in mice. PLoS One (2013) 0.99

Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr⁻/⁻ mice. J Lipid Res (2012) 0.98

MicroRNA-29b inhibits diabetic nephropathy in db/db mice. Mol Ther (2013) 0.95

Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol (2010) 0.92

Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells. PLoS One (2012) 0.91

Antioxidant and cytotoxic activities of Centella asiatica (L) Urb. Int J Mol Sci (2009) 0.89

Smad7 inhibits AngII-mediated hypertensive nephropathy in a mouse model of hypertension. Clin Sci (Lond) (2014) 0.87

Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21. Endocrinology (2015) 0.86

GQ5 Hinders Renal Fibrosis in Obstructive Nephropathy by Selectively Inhibiting TGF-β-Induced Smad3 Phosphorylation. J Am Soc Nephrol (2014) 0.85

Asiatic acid ameliorates tubulointerstitial fibrosis in mice with ureteral obstruction. Exp Ther Med (2013) 0.80

An improved HPLC method for quantitative determination of six triterpenes in Centella asiatica extracts and commercial products. Pharmazie (2003) 0.79

Smad7 protects against chronic aristolochic acid nephropathy in mice. Oncotarget (2015) 0.79